Appears On
Episode Appearances
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
“Disagreed with staff on T-Zield expansion approval, leading to Sanofi's withdrawal from priority program”
FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher program
View Analysis